Halozyme Therapeutics (HALO) opened 2026 with Q1 revenue of US$376.7 million and basic EPS of US$1.27, against a backdrop where trailing 12 month revenue sits at about US$1.5 billion and EPS at US$2.94. Over recent quarters, the company has seen revenue move from US$298.0 million in Q4 2024 to US$264.9 million in Q1 2025, then to US$325.7 million in Q2 2025, US$354.3 million in Q3 2025, US$451.8 million in Q4 2025, before the latest US$376.7 million print. Quarterly basic EPS has ranged from US$1.08 to US$1.49 in profitable quarters and included a Q4 2025 loss of US$1.20 per share, setting up an earnings season where investors are likely to focus on how consistently the current margin profile can be sustained.

See our full analysis for Halozyme Therapeutics.

With the headline numbers on the table, the next step is to see how these results line up with the widely followed narratives about Halozyme's growth, risks, and profitability, and where those stories may need to be updated.

Net margin reset after one off loss

• On a trailing 12 month basis, Halozyme earned US$348.8 million of net income on US$1.5b of revenue, a 23.1% net margin compared with 44.8% a year earlier, and this period includes a one off loss of US$349.3 million in the data.
• Consensus narrative links Halozyme’s profit story to the shift toward subcutaneous drug delivery, and this earnings profile both supports and tests that idea:
  • Support comes from the fact that trailing revenue reached US$1.5b and trailing EPS was US$2.94, which aligns with the view that the ENHANZE platform is tied into a broad base of biologic therapies generating recurring royalties.
  • Tension with the consensus view appears in the lower 23.1% margin and that large one off charge, which shows that even as partners roll out more ENHANZE based products, reported profitability can still swing meaningfully when unusual items or cost pressures show up.

Q1 profit steadier than recent swing

• Q1 2026 net income of US$150.0 million compares with a Q4 2025 net loss of US$141.6 million and Q3 2025 net income of US$175.2 million, so the latest quarter sits within the recent profit range but without the loss that affected the prior quarter.
• Bears focus on earnings volatility and dependence on ENHANZE, and this pattern gives them mixed evidence:
  • Critics highlight that trailing net margins fell from 44.8% to 23.1% and that results recently included a one off US$349.3 million loss, which fits the cautious view that profits can be hit hard when legal, patent, or pricing issues arise around the core platform.
  • At the same time, Q1 2026 EPS of US$1.27 and net income of US$150.0 million show the company returning to profitability quickly after the Q4 2025 loss, which challenges the idea that pressure on the ENHANZE franchise automatically leads to a prolonged earnings slump.

Skeptics point to that recent loss and patent risks as reasons to be careful, so it can be useful to see how the more cautious thesis lines up with the full bear case narrative 🐻 Halozyme Therapeutics Bear Case.

Growth and valuation pulling in different directions

• Analysts in the data expect earnings to grow about 12.3% per year while revenue is forecast to grow around 5.7% per year, and the stock trades at a trailing P/E of 24.1x versus an analyst target of US$85.44 and a DCF fair value of about US$211.59, compared with the current share price of US$70.93.
• Bulls argue that partner launches and ENHANZE adoption can support stronger earnings power than simple revenue growth suggests, and the numbers here partly back that case:
  • Support for the bullish view comes from the gap between the current price of US$70.93 and the DCF fair value of roughly US$211.59, alongside trailing 12 month revenue of US$1.5b and TTM EPS of US$2.94, which together indicate a business already generating meaningful profits and cash flows relative to its size.
  • On the other hand, the relatively rich 24.1x P/E and revenue growth expectations of 5.7% per year, which sit below the forecast 11.6% for the broader US market in the data, give investors a reason to question how much of the bullish ENHANZE story is already reflected in the multiple.

If you want to see how bullish investors connect these growth and valuation numbers back to ENHANZE adoption and long term royalty streams, it is worth reading the full bull case narrative 🐂 Halozyme Therapeutics Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Halozyme Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing up both the cautious points and the optimism in this earnings story, the quickest next step is to check the underlying data yourself and stress test your own thesis against the 3 key rewards and 4 important warning signs.

See What Else Is Out There

Halozyme's lower 23.1% trailing net margin, earnings volatility around a large one off loss, and higher 24.1x P/E leave some investors questioning consistency and value.

If those swings in profitability and debate around whether current pricing already assumes a strong future bother you, it is worth checking out 69 resilient stocks with low risk scores to focus on companies with steadier profiles and fewer surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.